• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CROX

    Crocs Inc.

    Subscribe to $CROX
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Crocs, Inc., together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children. It offers various footwear products, including sandals, wedges, flips, slides clogs, charms, and shoes under the Crocs brand name. The company sells its products in approximately 80 countries through wholesalers, retail stores, e-commerce sites, and third-party marketplaces. As of December 31, 2020, it had 186 outlet stores, 100 retail stores, 65 store-in-stores, and 13 company-operated e-commerce sites. The company serves in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Crocs, Inc. was founded in 1999 and is headquartered in Broomfield, Colorado.

    IPO Year: 2006

    Exchange: NASDAQ

    Website: crocs.com

    Peers

    $SCVL
    $SKX

    Recent Analyst Ratings for Crocs Inc.

    DatePrice TargetRatingAnalyst
    3/12/2025$110.00Hold → Buy
    Loop Capital
    11/22/2024$116.00Buy
    Needham
    11/7/2024$150.00 → $110.00Buy → Hold
    Loop Capital
    10/30/2024$170.00 → $140.00Buy
    Monness Crespi & Hardt
    10/30/2024Outperform → Mkt Perform
    Raymond James
    10/9/2024$182.00Buy
    Guggenheim
    8/23/2024$170.00Overweight
    Piper Sandler
    8/2/2024$164.00Strong Buy → Outperform
    Raymond James
    5/8/2024$140.00 → $170.00Buy
    Monness Crespi & Hardt
    4/1/2024$167.00Overweight
    Barclays
    See more ratings